QC Gyms Run GLP-1 Weekly Shots Through a Derma Side Door
Quezon City fitness studios resell semaglutide as a wellness package while the FDA registry draws a line between Ozempic and Wegovy the side door ignores.
Walk into a boutique gym off Tomas Morato on a Saturday and the front desk will quote you a package: 12 weeks, weekly shot, in-body scan, nutrition call. The injection happens in a back room with a derma logo on the door. The receipt says vitamin drip.
What's inside the syringe is semaglutide, the molecule behind both Ozempic and Wegovy. The Philippine FDA's registry lists Ozempic for type 2 diabetes. Wegovy, the weight-loss formulation, was approved by the FDA and launched locally by Novo Nordisk in April 2026, with injection strengths of 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg on the verification portal. The two products are not interchangeable on paper. The gym package treats them as if they are.
The side door is the business model
The setup is tidy. The gym owns the membership relationship. The derma clinic, often a single licensed physician renting a room two floors up or next door, owns the prescription pad. A nurse or aesthetician administers the shot. Payment runs through the gym's POS as a wellness bundle, sometimes split across Atome or BillEase.
Sourcing is where things blur. The legitimate channel runs through registered distributors to licensed prescribers. Parallel supply lines, unbranded vials, personal importation, and product diverted from the diabetes column to the cosmetic column, have been flagged by regulators across the region. Nobody at the front desk will tell you which vial is in the fridge.
Who is actually buying
The clients skew young, professional, and urban, the same demographic already buying preventive Botox on installment. The pitch lands because the alternative, a bariatric consult or a properly supervised endocrinology workup, costs more, takes longer, and requires admitting you want to lose weight before a wedding in November.
The packages are priced as wellness bundles and financed across several months, which makes the monthly line item look like a gym upgrade. The side effects, nausea, muscle loss, the rebound when you stop, tend to surface in group chats after the fact, not in the intake form.
What the FDA can and cannot do
The agency has issued advisories against unregistered semaglutide products and warned about counterfeit pens circulating in beauty channels. Enforcement is another matter. Inspections target pharmacies and online sellers. A gym is not a pharmacy. A derma clinic prescribing to a patient on its own books is harder to touch, and off-label prescribing itself is not illegal here.
The gap is the gym layer. A fitness studio is not licensed to dispense prescription drugs, but it is also not the entity writing the script or holding the vial on paper. The paperwork sits with the clinic. The customer sits on a bench in workout clothes.
The bill that lands later
Globally, the GLP-1 boom has tightened supply for diabetic patients who depend on these drugs to manage blood sugar. Endocrinology groups overseas have repeatedly warned that cosmetic demand competes with medical need at the pharmacy counter. The same dynamic plays out wherever the off-label market outruns the diabetes column.
The wellness bundle ends after 12 weeks. For users who stop without a maintenance plan, the weight tends to return. The clinic keeps the prescription record. The gym keeps the membership. The Type 2 patient at Mercury Drug keeps calling around for stock.
